27 – June 29. In the Federal medical biophysical center of name A.I. Burnazyana, the II International scientific and practical conference «Major problems of development, production and application of radiopharmaceuticals RADIOFARMA-2017 was held.»
The main goal of the conference was to carry out an open panel discussion between research organizations, medical centers, scientists, practitioners, young researchers and other specialists working in the field clinical and industrial application of a nuclear medicine.
The main organizers of the conference were Federal State Medical Biophysical Center of Name A.I. Burnazyana, company DIAMED, State corporation “RosAtom”, Medical scientific council of radiochemistry and the main scientific committee of a nuclear medicine. With the help of a Ministry of Education and Science of the Russian Federation and Ministry of Health, participants had the opportunity to exchange their knowledge, share their latest developments and scientific achievements.
The main topics of the conference were innovative developments in the field of radiopharmaceutical manufacturing, medical and industrial application of radiochemical technologies, methods of quality control, training opportunities for young professionals within research institutions, nuclear diagnostic and imagining and many other. Within the conference main leading experts of the European association of a nuclear medicine gave lectures, attendee took part in a round table that was an open panel discussion between researchers and industries, and scientists had the opportunity to join master classes teaching major aspects of radiopharmaceutical manufacturing and quality control. Finally, at the end of the session, organizational committee decided on the winner within your researchers, who presented their work.
Pharm-Sintez.Lab also took part in the conference as one of the main sponsors. Additionally, CEO of the company Lev Voloznev presented his own report: « Pharmacoeconomical cost and benefit analysis of radiopharmaceuticals for therapy of metastatic bone cancer».